Showing results (1661-1670 of 4,521) with videos related to

Sort By:
Pageof 453
Future Oncology (London, England)|July 3, 2025
The significance of mitochondrial DNA changes during the onset and progression of head and neck squamous cell carcinomaAmnani Aminuddin, Poh Kuan Wong, Siti Fathiah Masre, et al.
Future Oncology (London, England)|January 6, 2026
A Phase III study of perioperative dostarlimab in patients with dMMR/MSI-H resectable colon cancer: AZUR-2 study designNaureen Starling, Elena Elez, John H Strickler, et al.
Future Oncology (London, England)|January 6, 2026
MDX-2001-101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumorsEcaterina Dumbrava, Anna Minchom, Jason Henry, et al.
Future Oncology (London, England)|December 30, 2025
Plasma endogenous metabolome as superior biomarkers for adverse effects compared to drug and its metabolitesMingming Li, Tao Yan, Jiani Chen, et al.
Future Oncology (London, England)|December 30, 2025
Impact of radiation dose to immune cells on survival in patients with extensive-stage small cell lung cancer receiving consolidative thoracic radiotherapy after chemoimmunotherapyChangxing Feng, Kang Wang, Fuhao Xu, et al.
Future Oncology (London, England)|December 15, 2025
Impact of community recruitment and inclusion initiatives on enrollment in the biomarker-driven MyTACTIC trialRichard M Zuniga, Ari VanderWalde, Lee S Schwartzberg, et al.
Future Oncology (London, England)|December 17, 2025
Feasibility of antibiotic-assisted fecal microbiota transplantation with immunotherapy for esophageal and gastric cancerYuri Yoshinami, Shotaro Yamaguchi, Hirokazu Shoji, et al.
Future Oncology (London, England)|December 23, 2025
Clinicopathological significance of common PIK3CA exon mutations in non-metastatic colorectal cancerJin-Xu Chen, Xiao-Hang Song, Xiao Yang, et al.
Future Oncology (London, England)|April 13, 2025
ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, ESR1-mutated, metastatic breast cancerMatthew P Goetz, Seth A Wander, Thomas Bachelot, et al.
Future Oncology (London, England)|May 27, 2025
Post-marketing surveillance of tirabrutinib in 189 patients with r/r primary central nervous system lymphomaAkira Kawasaki, Ichiro Matsumoto, Koji Izutsu, et al.
Pageof 453